Cell therapy is one of the most exciting and rapidly developing frontiers in modern medicine, with potential to alleviate or cure diseases that have perplexed researchers for decades. Through a new partnership with Hitachi Chemical Advanced Therapeutics, Invetech is helping drive the development of these life-changing therapies in an efficient and cost-effective way.
Invetech’s breakthrough counterflow centrifuge technology enables researchers to more effectively develop new cell-based therapies. The platform automates common cell processing functions across the therapy development cycle, from research and clinical trials all the way to commercial manufacturing.
This is an exciting development for Invetech, bringing one of the company’s leading-edge technologies to market in a way that really makes a difference in the world.
SAN DIEGO, CA (June 5, 2018) – Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of regenerative medicine products, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced a collaboration agreement to commercialize an automated platform for cell therapy manufacturing, the Counter-Flow Centrifugation system (CFC). The collaboration will significantly enhance the development and manufacturing capability available to the cell therapy market, helping to deliver commercially viable therapies to patients in need, more quickly, at reduced cost and with greater product confidence.
For more information, contact: